Eli Lilly and Co (LLY)
734.97
-20.94
(-2.77%)
USD |
NYSE |
May 03, 16:00
738.49
+3.52
(+0.48%)
Pre-Market: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 698.52B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 71.87% |
Valuation | |
PE Ratio | 110.09 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 18.46 |
Price to Book Value | 54.52 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 1.30 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 2.046 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 22.48% |
Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | Aug. 08, 2024 |
Last Earnings Release | Apr. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 14, 2024 |
Ratings
Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | Aug. 08, 2024 |
Last Earnings Release | Apr. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 14, 2024 |